Alison Schram
Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alison Schram as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03310541 · AZD5363 in Patients With Advanced Solid Tumors Harboring AKT MutationsMemorial Sloan Kettering Cancer Center · completed · Breast Cancer, Prostate Cancer, Advanced Solid Tumors · principal investigator
- Ph2NCT02912949 · A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Partner Therapeutics, Inc. · active not recruiting · Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:29 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- 650 citationsRCR 20.3
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.Cancer Discov · 2017364 citationsRCR 10.2
- Surgery versus physiotherapy for stress urinary incontinence.N Engl J Med · 2013126 citationsRCR 5.9
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.N Engl J Med · 2025122 citationsRCR 24.2
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Cancer Discov · 202099 citationsRCR 3.3
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.Br J Cancer · 201888 citationsRCR 2.7
- Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.ESMO Open · 202237 citationsRCR 2.2
- 34 citationsRCR 2.3
- Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Nat Med · 202427 citationsRCR 2.4
- 25 citationsRCR 12.5